COVID-19-associated mucormycosis: an update of anesthetic management | ||||
| Ain-Shams Journal of Anesthesiology | ||||
| Volume 14, Issue 1, January 2022 PDF (485.29 K) | ||||
| DOI: 10.1186/s42077-022-00216-3 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Nilesh Maganbhai Solanki   ; Rekha Nilesh Solanki; Arun Vrajlal Madaliya; Rasmita Haresh Jasoliya; Dhara Tushar Upadhyay
| ||||
| Abstract | ||||
| Background Mucormycosis is uncommon, progressive fungal infection with mortality rate on higher side. The anesthetic management of surgical debridement in mucormycosis is challenging. Results Fifty-six patients presented with uncontrolled diabetes mellitus. All patients had history of COVID-19 infection and received steroid during treatment. Nasal endoscopic debridement was done in 43 patients, total maxillectomy in 14 patients. Temporalis flap was needed in five patients, and orbital exenteration was required in three patients. Central venous catheter was inserted in 17 patients, and invasive arterial monitoring was done in ten patients. All patients administered lyophilized amphotericin B (deoxycholate) in combination with surgical debridement. Conclusions Challenges include difficult intubation and renal function impairment due to prolonged antifungal therapy. Postoperative ICU management is important in mucormycosis patients due to comorbidities and rapid progressive infection after surgery. | ||||
| Keywords | ||||
| COVID-19; Diabetes mellitus; Fungal infection; mucormycosis; nasal endoscopic; Ophthalmic infection | ||||
|
Statistics Article View: 23 PDF Download: 14 |
||||
